KeyBanc analyst Matthew Mishan maintained a Buy rating on Icu Medical on Friday, setting a price target of $236, which is approximately 7.28% above the present share price of $219.99.
Mishan expects Icu Medical to post earnings per share (EPS) of $1.19 for the first quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in ICU Medical (NASDAQ:ICUI), with an average price target of $236.
The analysts price targets range from a high of $236 to a low of $236.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $318.57 million and a net profit of $32.94 million. The company's market cap is $4.62 billion.
According to TipRanks.com, KeyBanc analyst Matthew Mishan is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.9% and a 75.00% success rate.
ICU Medical, Inc. is an infusion therapy company, which engages in the development, manufacturing and sale of innovative medical devices used in vascular therapy and critical care applications. The company's product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needle-free connectors designed to help meet clinical, safety and workflow goals. Its customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as clinics, home health care providers and long-term care facilities. The company was founded by George A. Lopez in 1984 and is headquartered in San Clemente, CA.